GRM1 and Cognitive impairment: As mGlu1 PAM development continues toward producing a clinical candidate, our study provides preclinical proof of concept that mGlu1 PAMs rescue cognitive deficits in addition to their previously observed antipsychotic-like efficacy (Yohn et al., 2020).